Biomarker assay validation for clinical trials: a questionnaire survey to pharmaceutical companies in Japan
While some biomarker assays use the same methodologies (e.g.,ligand-binding assays and chromatographic assays) as pharmacokinetics (PK) assays, there are some differences in points to consider in assay validation between biomarker assays and PK assays. [...]biomarker assay validation has been a hot...
Gespeichert in:
| Veröffentlicht in: | Bioanalysis 2019-01, Vol.11 (2), p.55-60 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 60 |
|---|---|
| container_issue | 2 |
| container_start_page | 55 |
| container_title | Bioanalysis |
| container_volume | 11 |
| creator | Ohtsu, Yoshiaki Matsumaru, Takehisa Katashima, Masataka Kakehi, Masaaki Kakuo, Hiroyuki Suzuki, Takayoshi Mabuchi, Masanari Nakamura, Ryosuke Nakamura, Takahiro Katori, Noriko Tanaka, Seiji Saito, Yoshiro |
| description | While some biomarker assays use the same methodologies (e.g.,ligand-binding assays and chromatographic assays) as pharmacokinetics (PK) assays, there are some differences in points to consider in assay validation between biomarker assays and PK assays. [...]biomarker assay validation has been a hot topic in bioanalysis conferences and communities. The only survey was conducted within European and North American CROs by Global CRO Council for Bioanalysis (GCC) in 2012 (9).To investigate the current situation in the pharmaceutical companies, the biomarker working group (WG) in the bioanalytical assay validation study group, which was subsidized by the Japan Agency for Medical Research and Development, decided to conduct a questionnaire survey in Japan (10). According to the present survey, the same biological matrix as study samples was used in 39.0% of the assays, whereas the surrogate matrix (such as water, buffer, solution included in commercial kits, protein solution, stripped matrix) was used in 37.8% of the assays. According to the survey results, the majority of biomarker assays consisted of three types as follows: chromatographic assays to be developed de novo,ligand-binding assays to be developed de novoand ligand-binding assays using commercial kits. |
| doi_str_mv | 10.4155/bio-2018-0257 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2216550937</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2216550937</sourcerecordid><originalsourceid>FETCH-LOGICAL-c410t-604458fd7ab088a1b79535aa5fb1473b50303e9313058c8454c5085adc05692e3</originalsourceid><addsrcrecordid>eNp1kE1PGzEQhi1UVBDk2Gtlqedtx2tPbPfWIkpBSFzgbM06XmGSrFN7Fyn_HucDbvXFY80zr0cPY18EfFcC8UcXU9OCMA20qE_YudCom7mw9tNHbeCMzUp5gXpka6yyn9mZBKURdHvOlr9jWlNehsypFNryV1rFBY0xDbxPmftVHKKnFR9zpFX5yYn_m0LZ9QeKOfAy5dew5WPim2fKa_JhGvcDPq03NMRQeBz4HdX6kp32NSPMjvcFe_pz_Xj1t7l_uLm9-nXfeCVgbOagFJp-oakDY0h02qJEIuw7obTsECTIYKWQgMYbhcojGKSFB5zbNsgL9u2Qu8lpv6x7SVMe6peubcUcEazUlWoOlM-plBx6t8mxqtg6AW5n11W7bmfX7exW_usxderWYfFBv7usgD0A_TROORQfw-CDO7zqRPRxCP8JfwOFeojt</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2216550937</pqid></control><display><type>article</type><title>Biomarker assay validation for clinical trials: a questionnaire survey to pharmaceutical companies in Japan</title><source>MEDLINE</source><source>PubMed Central</source><creator>Ohtsu, Yoshiaki ; Matsumaru, Takehisa ; Katashima, Masataka ; Kakehi, Masaaki ; Kakuo, Hiroyuki ; Suzuki, Takayoshi ; Mabuchi, Masanari ; Nakamura, Ryosuke ; Nakamura, Takahiro ; Katori, Noriko ; Tanaka, Seiji ; Saito, Yoshiro</creator><creatorcontrib>Ohtsu, Yoshiaki ; Matsumaru, Takehisa ; Katashima, Masataka ; Kakehi, Masaaki ; Kakuo, Hiroyuki ; Suzuki, Takayoshi ; Mabuchi, Masanari ; Nakamura, Ryosuke ; Nakamura, Takahiro ; Katori, Noriko ; Tanaka, Seiji ; Saito, Yoshiro</creatorcontrib><description>While some biomarker assays use the same methodologies (e.g.,ligand-binding assays and chromatographic assays) as pharmacokinetics (PK) assays, there are some differences in points to consider in assay validation between biomarker assays and PK assays. [...]biomarker assay validation has been a hot topic in bioanalysis conferences and communities. The only survey was conducted within European and North American CROs by Global CRO Council for Bioanalysis (GCC) in 2012 (9).To investigate the current situation in the pharmaceutical companies, the biomarker working group (WG) in the bioanalytical assay validation study group, which was subsidized by the Japan Agency for Medical Research and Development, decided to conduct a questionnaire survey in Japan (10). According to the present survey, the same biological matrix as study samples was used in 39.0% of the assays, whereas the surrogate matrix (such as water, buffer, solution included in commercial kits, protein solution, stripped matrix) was used in 37.8% of the assays. According to the survey results, the majority of biomarker assays consisted of three types as follows: chromatographic assays to be developed de novo,ligand-binding assays to be developed de novoand ligand-binding assays using commercial kits.</description><identifier>ISSN: 1757-6180</identifier><identifier>EISSN: 1757-6199</identifier><identifier>DOI: 10.4155/bio-2018-0257</identifier><identifier>PMID: 30475072</identifier><language>eng</language><publisher>England: Future Science Ltd</publisher><subject>assay validation ; Biological Assay - statistics & numerical data ; biomarker ; Biomarkers ; Biomarkers - analysis ; Cancer ; Chromatography ; Clinical trials ; Clinical Trials as Topic - methods ; Clinical Trials as Topic - statistics & numerical data ; Critical path ; Drug Discovery - methods ; Drug Discovery - statistics & numerical data ; Drug Industry - statistics & numerical data ; Japan ; Ligands ; Medical research ; Methods ; Pharmaceutical industry ; Pharmaceutical Preparations ; Pharmaceutical sciences ; Pharmacokinetics ; Questionnaires ; standard operating procedure ; Surveys and Questionnaires</subject><ispartof>Bioanalysis, 2019-01, Vol.11 (2), p.55-60</ispartof><rights>2018 Newlands Press</rights><rights>Copyright Newlands Press Jan 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c410t-604458fd7ab088a1b79535aa5fb1473b50303e9313058c8454c5085adc05692e3</citedby><cites>FETCH-LOGICAL-c410t-604458fd7ab088a1b79535aa5fb1473b50303e9313058c8454c5085adc05692e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30475072$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ohtsu, Yoshiaki</creatorcontrib><creatorcontrib>Matsumaru, Takehisa</creatorcontrib><creatorcontrib>Katashima, Masataka</creatorcontrib><creatorcontrib>Kakehi, Masaaki</creatorcontrib><creatorcontrib>Kakuo, Hiroyuki</creatorcontrib><creatorcontrib>Suzuki, Takayoshi</creatorcontrib><creatorcontrib>Mabuchi, Masanari</creatorcontrib><creatorcontrib>Nakamura, Ryosuke</creatorcontrib><creatorcontrib>Nakamura, Takahiro</creatorcontrib><creatorcontrib>Katori, Noriko</creatorcontrib><creatorcontrib>Tanaka, Seiji</creatorcontrib><creatorcontrib>Saito, Yoshiro</creatorcontrib><title>Biomarker assay validation for clinical trials: a questionnaire survey to pharmaceutical companies in Japan</title><title>Bioanalysis</title><addtitle>Bioanalysis</addtitle><description>While some biomarker assays use the same methodologies (e.g.,ligand-binding assays and chromatographic assays) as pharmacokinetics (PK) assays, there are some differences in points to consider in assay validation between biomarker assays and PK assays. [...]biomarker assay validation has been a hot topic in bioanalysis conferences and communities. The only survey was conducted within European and North American CROs by Global CRO Council for Bioanalysis (GCC) in 2012 (9).To investigate the current situation in the pharmaceutical companies, the biomarker working group (WG) in the bioanalytical assay validation study group, which was subsidized by the Japan Agency for Medical Research and Development, decided to conduct a questionnaire survey in Japan (10). According to the present survey, the same biological matrix as study samples was used in 39.0% of the assays, whereas the surrogate matrix (such as water, buffer, solution included in commercial kits, protein solution, stripped matrix) was used in 37.8% of the assays. According to the survey results, the majority of biomarker assays consisted of three types as follows: chromatographic assays to be developed de novo,ligand-binding assays to be developed de novoand ligand-binding assays using commercial kits.</description><subject>assay validation</subject><subject>Biological Assay - statistics & numerical data</subject><subject>biomarker</subject><subject>Biomarkers</subject><subject>Biomarkers - analysis</subject><subject>Cancer</subject><subject>Chromatography</subject><subject>Clinical trials</subject><subject>Clinical Trials as Topic - methods</subject><subject>Clinical Trials as Topic - statistics & numerical data</subject><subject>Critical path</subject><subject>Drug Discovery - methods</subject><subject>Drug Discovery - statistics & numerical data</subject><subject>Drug Industry - statistics & numerical data</subject><subject>Japan</subject><subject>Ligands</subject><subject>Medical research</subject><subject>Methods</subject><subject>Pharmaceutical industry</subject><subject>Pharmaceutical Preparations</subject><subject>Pharmaceutical sciences</subject><subject>Pharmacokinetics</subject><subject>Questionnaires</subject><subject>standard operating procedure</subject><subject>Surveys and Questionnaires</subject><issn>1757-6180</issn><issn>1757-6199</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kE1PGzEQhi1UVBDk2Gtlqedtx2tPbPfWIkpBSFzgbM06XmGSrFN7Fyn_HucDbvXFY80zr0cPY18EfFcC8UcXU9OCMA20qE_YudCom7mw9tNHbeCMzUp5gXpka6yyn9mZBKURdHvOlr9jWlNehsypFNryV1rFBY0xDbxPmftVHKKnFR9zpFX5yYn_m0LZ9QeKOfAy5dew5WPim2fKa_JhGvcDPq03NMRQeBz4HdX6kp32NSPMjvcFe_pz_Xj1t7l_uLm9-nXfeCVgbOagFJp-oakDY0h02qJEIuw7obTsECTIYKWQgMYbhcojGKSFB5zbNsgL9u2Qu8lpv6x7SVMe6peubcUcEazUlWoOlM-plBx6t8mxqtg6AW5n11W7bmfX7exW_usxderWYfFBv7usgD0A_TROORQfw-CDO7zqRPRxCP8JfwOFeojt</recordid><startdate>20190101</startdate><enddate>20190101</enddate><creator>Ohtsu, Yoshiaki</creator><creator>Matsumaru, Takehisa</creator><creator>Katashima, Masataka</creator><creator>Kakehi, Masaaki</creator><creator>Kakuo, Hiroyuki</creator><creator>Suzuki, Takayoshi</creator><creator>Mabuchi, Masanari</creator><creator>Nakamura, Ryosuke</creator><creator>Nakamura, Takahiro</creator><creator>Katori, Noriko</creator><creator>Tanaka, Seiji</creator><creator>Saito, Yoshiro</creator><general>Future Science Ltd</general><general>Newlands Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20190101</creationdate><title>Biomarker assay validation for clinical trials: a questionnaire survey to pharmaceutical companies in Japan</title><author>Ohtsu, Yoshiaki ; Matsumaru, Takehisa ; Katashima, Masataka ; Kakehi, Masaaki ; Kakuo, Hiroyuki ; Suzuki, Takayoshi ; Mabuchi, Masanari ; Nakamura, Ryosuke ; Nakamura, Takahiro ; Katori, Noriko ; Tanaka, Seiji ; Saito, Yoshiro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c410t-604458fd7ab088a1b79535aa5fb1473b50303e9313058c8454c5085adc05692e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>assay validation</topic><topic>Biological Assay - statistics & numerical data</topic><topic>biomarker</topic><topic>Biomarkers</topic><topic>Biomarkers - analysis</topic><topic>Cancer</topic><topic>Chromatography</topic><topic>Clinical trials</topic><topic>Clinical Trials as Topic - methods</topic><topic>Clinical Trials as Topic - statistics & numerical data</topic><topic>Critical path</topic><topic>Drug Discovery - methods</topic><topic>Drug Discovery - statistics & numerical data</topic><topic>Drug Industry - statistics & numerical data</topic><topic>Japan</topic><topic>Ligands</topic><topic>Medical research</topic><topic>Methods</topic><topic>Pharmaceutical industry</topic><topic>Pharmaceutical Preparations</topic><topic>Pharmaceutical sciences</topic><topic>Pharmacokinetics</topic><topic>Questionnaires</topic><topic>standard operating procedure</topic><topic>Surveys and Questionnaires</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ohtsu, Yoshiaki</creatorcontrib><creatorcontrib>Matsumaru, Takehisa</creatorcontrib><creatorcontrib>Katashima, Masataka</creatorcontrib><creatorcontrib>Kakehi, Masaaki</creatorcontrib><creatorcontrib>Kakuo, Hiroyuki</creatorcontrib><creatorcontrib>Suzuki, Takayoshi</creatorcontrib><creatorcontrib>Mabuchi, Masanari</creatorcontrib><creatorcontrib>Nakamura, Ryosuke</creatorcontrib><creatorcontrib>Nakamura, Takahiro</creatorcontrib><creatorcontrib>Katori, Noriko</creatorcontrib><creatorcontrib>Tanaka, Seiji</creatorcontrib><creatorcontrib>Saito, Yoshiro</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Bioanalysis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ohtsu, Yoshiaki</au><au>Matsumaru, Takehisa</au><au>Katashima, Masataka</au><au>Kakehi, Masaaki</au><au>Kakuo, Hiroyuki</au><au>Suzuki, Takayoshi</au><au>Mabuchi, Masanari</au><au>Nakamura, Ryosuke</au><au>Nakamura, Takahiro</au><au>Katori, Noriko</au><au>Tanaka, Seiji</au><au>Saito, Yoshiro</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Biomarker assay validation for clinical trials: a questionnaire survey to pharmaceutical companies in Japan</atitle><jtitle>Bioanalysis</jtitle><addtitle>Bioanalysis</addtitle><date>2019-01-01</date><risdate>2019</risdate><volume>11</volume><issue>2</issue><spage>55</spage><epage>60</epage><pages>55-60</pages><issn>1757-6180</issn><eissn>1757-6199</eissn><abstract>While some biomarker assays use the same methodologies (e.g.,ligand-binding assays and chromatographic assays) as pharmacokinetics (PK) assays, there are some differences in points to consider in assay validation between biomarker assays and PK assays. [...]biomarker assay validation has been a hot topic in bioanalysis conferences and communities. The only survey was conducted within European and North American CROs by Global CRO Council for Bioanalysis (GCC) in 2012 (9).To investigate the current situation in the pharmaceutical companies, the biomarker working group (WG) in the bioanalytical assay validation study group, which was subsidized by the Japan Agency for Medical Research and Development, decided to conduct a questionnaire survey in Japan (10). According to the present survey, the same biological matrix as study samples was used in 39.0% of the assays, whereas the surrogate matrix (such as water, buffer, solution included in commercial kits, protein solution, stripped matrix) was used in 37.8% of the assays. According to the survey results, the majority of biomarker assays consisted of three types as follows: chromatographic assays to be developed de novo,ligand-binding assays to be developed de novoand ligand-binding assays using commercial kits.</abstract><cop>England</cop><pub>Future Science Ltd</pub><pmid>30475072</pmid><doi>10.4155/bio-2018-0257</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1757-6180 |
| ispartof | Bioanalysis, 2019-01, Vol.11 (2), p.55-60 |
| issn | 1757-6180 1757-6199 |
| language | eng |
| recordid | cdi_proquest_journals_2216550937 |
| source | MEDLINE; PubMed Central |
| subjects | assay validation Biological Assay - statistics & numerical data biomarker Biomarkers Biomarkers - analysis Cancer Chromatography Clinical trials Clinical Trials as Topic - methods Clinical Trials as Topic - statistics & numerical data Critical path Drug Discovery - methods Drug Discovery - statistics & numerical data Drug Industry - statistics & numerical data Japan Ligands Medical research Methods Pharmaceutical industry Pharmaceutical Preparations Pharmaceutical sciences Pharmacokinetics Questionnaires standard operating procedure Surveys and Questionnaires |
| title | Biomarker assay validation for clinical trials: a questionnaire survey to pharmaceutical companies in Japan |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T09%3A42%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Biomarker%20assay%20validation%20for%20clinical%20trials:%20a%20questionnaire%20survey%20to%20pharmaceutical%20companies%20in%20Japan&rft.jtitle=Bioanalysis&rft.au=Ohtsu,%20Yoshiaki&rft.date=2019-01-01&rft.volume=11&rft.issue=2&rft.spage=55&rft.epage=60&rft.pages=55-60&rft.issn=1757-6180&rft.eissn=1757-6199&rft_id=info:doi/10.4155/bio-2018-0257&rft_dat=%3Cproquest_cross%3E2216550937%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2216550937&rft_id=info:pmid/30475072&rfr_iscdi=true |